• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

阿扑吗啡对亨廷顿舞蹈症的急性激发试验:一项双盲研究。

Acute challenge with apomorphine in Huntington's disease: a double-blind study.

作者信息

Albanese A, Cassetta E, Carretta D, Bentivoglio A R, Tonali P

机构信息

Istituto di Neurologia, Università Cattolica del Sacro Cuore, Rome, Italy.

出版信息

Clin Neuropharmacol. 1995 Oct;18(5):427-34. doi: 10.1097/00002826-199510000-00005.

DOI:10.1097/00002826-199510000-00005
PMID:8665556
Abstract

Apomorphine (1.5 or 3 mg) or placebo was acutely administered to choreic patients affected by Huntington's disease in a double-blind fashion. The patients were evaluated before the administration, and at 15-min intervals for 2 h afterward, by means of a rating scale for Huntington's disease. As compared to baseline, the total score improved by 38.54% after 1.5 mg and by 30.41% after 3 mg; no variations were observed after placebo. Several items of the scale improved after the administration of 1.5 mg. An average 35.25% improvement was observed in items measuring the intensity of chorea (at rest, with arms outstretched, during conversation, and voluntary movements of the limbs); in addition, motor impersistence (as measured by tongue protrusion) and the capability to suppress associated movements (as measured by head movements during saccades) improved by an average of 31.46 and 61%, respectively. Some items of the scale improved after the administration of 3 mg. Items measuring the intensity of chorea improved by an average of 30.41%; in addition, the extent of vertical gaze improved by 63.77%. These data indicate that apomorphine brings about a transient symptomatic improvement of chorea and of other associated clinical features in Huntington's disease. The time course observed for the antichoreic activity is only partially consistent with the antiparkinsonian action of apomorphine.

摘要

以双盲方式对患有亨廷顿舞蹈症的舞蹈症患者急性给予阿扑吗啡(1.5毫克或3毫克)或安慰剂。在给药前以及给药后2小时内每隔15分钟,通过亨廷顿舞蹈症评定量表对患者进行评估。与基线相比,1.5毫克阿扑吗啡给药后总分提高了38.54%,3毫克阿扑吗啡给药后总分提高了30.41%;安慰剂给药后未观察到变化。给予1.5毫克阿扑吗啡后,量表的几个项目有所改善。在测量舞蹈症强度(休息时、手臂伸展时、交谈时以及肢体自主运动时)的项目中,平均改善了35.25%;此外,运动不能持续(通过伸舌测量)和抑制关联运动的能力(通过扫视时的头部运动测量)分别平均改善了31.46%和61%。给予3毫克阿扑吗啡后,量表的一些项目有所改善。测量舞蹈症强度的项目平均改善了30.41%;此外,垂直凝视范围改善了63.77%。这些数据表明,阿扑吗啡可使亨廷顿舞蹈症的舞蹈症及其他相关临床特征产生短暂的症状改善。观察到的抗舞蹈症活性的时间进程仅部分与阿扑吗啡的抗帕金森作用一致。

相似文献

1
Acute challenge with apomorphine in Huntington's disease: a double-blind study.阿扑吗啡对亨廷顿舞蹈症的急性激发试验:一项双盲研究。
Clin Neuropharmacol. 1995 Oct;18(5):427-34. doi: 10.1097/00002826-199510000-00005.
2
Apomorphine hydrochloride-induced improvement in Huntington's chorea: stimulation of dopamine receptor.盐酸阿扑吗啡诱导的亨廷顿舞蹈症改善:多巴胺受体的刺激
Arch Neurol. 1978 Jan;35(1):27-30. doi: 10.1001/archneur.1978.00500250031006.
3
Short-term continuous infusion of apomorphine hydrochloride for treatment of Huntington's chorea: A double blind, randomized cross-over trial.短期持续输注盐酸阿扑吗啡治疗亨廷顿舞蹈症:一项双盲、随机交叉试验。
Mov Disord. 2007 Dec;22(16):2359-64. doi: 10.1002/mds.21718.
4
Clozapine versus placebo in Huntington's disease: a double blind randomised comparative study.氯氮平与安慰剂治疗亨廷顿舞蹈症的双盲随机对照研究
J Neurol Neurosurg Psychiatry. 1997 Jul;63(1):35-9. doi: 10.1136/jnnp.63.1.35.
5
Effects of DA agonist in Huntington disease hyperkinesia.多巴胺激动剂对亨廷顿病运动增多的影响。
Ital J Neurol Sci. 1980 Jun;1(3):155-61. doi: 10.1007/BF02335845.
6
Pridopidine for the treatment of motor function in patients with Huntington's disease (MermaiHD): a phase 3, randomised, double-blind, placebo-controlled trial.普里多吡啶治疗亨廷顿病患者的运动功能障碍(MermaiHD):一项 3 期、随机、双盲、安慰剂对照试验。
Lancet Neurol. 2011 Dec;10(12):1049-57. doi: 10.1016/S1474-4422(11)70233-2. Epub 2011 Nov 7.
7
Safety, tolerability, and efficacy of PBT2 in Huntington's disease: a phase 2, randomised, double-blind, placebo-controlled trial.PBT2 治疗亨廷顿病的安全性、耐受性和疗效:一项 2 期、随机、双盲、安慰剂对照试验。
Lancet Neurol. 2015 Jan;14(1):39-47. doi: 10.1016/S1474-4422(14)70262-5. Epub 2014 Nov 14.
8
Dosage effects of riluzole in Huntington's disease: a multicenter placebo-controlled study.利鲁唑治疗亨廷顿舞蹈症的剂量效应:一项多中心安慰剂对照研究。
Neurology. 2003 Dec 9;61(11):1551-6. doi: 10.1212/01.wnl.0000096019.71649.2b.
9
A randomized, double-blind, placebo-controlled trial of pridopidine in Huntington's disease.普里多宾治疗亨廷顿病的随机、双盲、安慰剂对照试验。
Mov Disord. 2013 Sep;28(10):1407-15. doi: 10.1002/mds.25362. Epub 2013 Feb 28.
10
Lithium treatment of Huntington's chorea. A placebo-controlled clinical trial.锂盐治疗亨廷顿舞蹈病。一项安慰剂对照临床试验。
Acta Psychiatr Scand. 1977 Sep;56(3):183-8. doi: 10.1111/j.1600-0447.1977.tb03561.x.

引用本文的文献

1
Update on the Symptomatic Treatment of Huntington's Disease: From Pathophysiology to Clinical Practice.亨廷顿舞蹈症对症治疗的最新进展:从病理生理学到临床实践
Int J Mol Sci. 2025 Jun 27;26(13):6220. doi: 10.3390/ijms26136220.
2
Evidence-Based Review on Symptomatic Management of Huntington's Disease.亨廷顿舞蹈症症状管理的循证综述
J Mov Disord. 2024 Oct;17(4):369-386. doi: 10.14802/jmd.24140. Epub 2024 Aug 9.
3
The Many Faces of Apomorphine: Lessons from the Past and Challenges for the Future.阿朴吗啡面面观:从过去的经验教训到未来的挑战。
Drugs R D. 2018 Jun;18(2):91-107. doi: 10.1007/s40268-018-0230-3.
4
The corticostriatal pathway in Huntington's disease.亨廷顿舞蹈病中的皮质纹状体通路。
Prog Neurobiol. 2007 Apr;81(5-6):253-71. doi: 10.1016/j.pneurobio.2006.11.001. Epub 2006 Dec 13.